Unknown

Dataset Information

0

Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.


ABSTRACT: PURPOSE:Bevacizumab treatment at 7.5 mg/kg every 3 weeks results in improved hearing in approximately 35%-40% of patients with neurofibromatosis type 2 (NF2) and progressive vestibular schwannomas (VSs). However, the optimal dose is unknown. In this multicenter phase II and biomarker study, we evaluated the efficacy and safety of high-dose bevacizumab in pediatric and adult patients with NF2 with progressive VS. PATIENTS AND METHODS:Bevacizumab was given for 6 months at 10 mg/kg every 2 weeks, followed by 18 months at 5 mg/kg every 3 weeks. The primary end point was hearing response defined by word recognition score (WRS) at 6 months. Secondary end points included toxicity, radiographic response, quality of life (QOL), and plasma biomarkers. RESULTS:Twenty-two participants with NF2 (median age, 23 years) with progressive hearing loss in the target ear (median baseline WRS, 53%) were enrolled. Nine (41%) of 22 participants achieved a hearing response at 6 months (1 of 7 children and 8 of 15 adults; P = .08). Radiographic response was seen in 7 (32%) of 22 patients with VS at 6 months (7 of 15 adults and 0 of 7 children; P = .05). Common mild to moderate adverse events included hypertension, fatigue, headache, and irregular menstruation. Improvement in NF2-related QOL and reduction in tinnitus-related distress were reported in 30% and 60% of participants, respectively. Paradoxically, high-dose bevacizumab treatment was not associated with a significant decrease in free vascular endothelial growth factor but was associated with increased carbonic anhydrase IX, hepatocyte growth factor, placental growth factor, stromal cell-derived factor 1?, and basic fibroblast growth factor concentrations in plasma. CONCLUSION:High-dose bevacizumab seems to be no more effective than standard-dose bevacizumab for treatment of patients with NF2 with hearing loss. In contrast to adults, pediatric participants did not experience tumor shrinkage. However, adult and pediatric participants reported similar improvement in QOL during induction. Novel approaches using bevacizumab should be considered for children with NF2.

SUBMITTER: Plotkin SR 

PROVIDER: S-EPMC7098833 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.

Plotkin Scott R SR   Duda Dan G DG   Muzikansky Alona A   Allen Jeffrey J   Blakeley Jaishri J   Rosser Tena T   Campian Jian L JL   Clapp D Wade DW   Fisher Michael J MJ   Tonsgard James J   Ullrich Nicole N   Thomas Coretta C   Cutter Gary G   Korf Bruce B   Packer Roger R   Karajannis Matthias A MA  

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20191018 35


<h4>Purpose</h4>Bevacizumab treatment at 7.5 mg/kg every 3 weeks results in improved hearing in approximately 35%-40% of patients with neurofibromatosis type 2 (NF2) and progressive vestibular schwannomas (VSs). However, the optimal dose is unknown. In this multicenter phase II and biomarker study, we evaluated the efficacy and safety of high-dose bevacizumab in pediatric and adult patients with NF2 with progressive VS.<h4>Patients and methods</h4>Bevacizumab was given for 6 months at 10 mg/kg e  ...[more]

Similar Datasets

| S-EPMC10398799 | biostudies-literature
| S-EPMC7881257 | biostudies-literature
| S-EPMC4778430 | biostudies-literature
| S-EPMC4872317 | biostudies-literature
| S-EPMC7828193 | biostudies-literature
| S-EPMC6827030 | biostudies-literature
| S-EPMC3177662 | biostudies-literature
| S-EPMC6594723 | biostudies-literature
| S-EPMC9830296 | biostudies-literature
| S-EPMC7212860 | biostudies-literature